| Literature DB >> 28497050 |
Jie Li1, Dan Hu2, Xiaoli Song3, Tao Han3, Yonghong Gao4, Yanwei Xing1.
Abstract
Arrhythmia is a disease that is caused by abnormal electrical activity in the heart rate or rhythm. It is the major cause of cardiovascular morbidity and mortality. Although several antiarrhythmic drugs have been used in clinic for decades, their application is often limited by their adverse effects. As a result, natural drugs, which have fewer side effects, are now being used to treat arrhythmias. We searched for all articles on the role of biologically active ingredients from natural drug treatments for arrhythmias in different mechanisms in PubMed. This study reviews 19 natural drug therapies, with 18 active ingredient therapies, such as alkaloids, flavonoids, saponins, quinones, and terpenes, and two kinds of traditional Chinese medicine compound (Wenxin-Keli and Shensongyangxin), all of which have been studied and reported as having antiarrhythmic effects. The primary focus is the proposed antiarrhythmic mechanism of each natural drug agent. Conclusion. We stress persistent vigilance on the part of the provider in discussing the use of natural drug agents to provide a solid theoretical foundation for further research on antiarrhythmia drugs.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28497050 PMCID: PMC5405360 DOI: 10.1155/2017/4615727
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Natural drug therapies with antiarrhythmic properties.
| Active ingredients | Chemical structure | Natural drug | Molecular formula | Mechanism of action | State of evidence | ||||
|---|---|---|---|---|---|---|---|---|---|
| IK | ICa | INa | APD | Others | |||||
| Alkaloid | Diterpenoid alkaloids | Aconitine | C34H47NO11 | Reduction in IKs | + | + | Prolong | — | In vitro/animal models |
| Isoquinoline | Berberine | C20H18NO4 | Reduction in Ito | − | − | — | — | In vitro/animal models | |
| Liensinine | C37H42N2O6 | Reduction in IKr | + | − | — | — | In vitro/animal models | ||
| Indole alkaloids | Rhynchophylline | C22H28N2O4 | — | + | − | — | — | In vitro/animal models | |
| Quinolizidine | Matrine | C15H24N2O2·H2O | Reduction in IKM3 | + | − | Prolong | — | Humans-RCT | |
| Alkaloids | Oxymatrine | C15H24N2O2 | + | + | — | — | In vitro/animal models | ||
| Sophocarpine | C2H22N2O | Reduction in IKr | + | + | Prolong | — | In vitro/animal models | ||
| Glycoside | Ginsenoside Rg1 | C42H72O14 | Reduction in IKr | − | − | — | — | In vitro/animal models | |
| Phenylpropanoid glycosides | C29H36O15 | Reduction in IKr | + | − | Prolong | — | In vitro/animal models | ||
| Flavonoid | Baicalein | C15H10O5 | — | − | − | — | Pal-LPC | In vitro/animal models | |
| Resveratrol | C14H12O3 | Reduction in IKs | + | + | Short | — | In vitro/animal models | ||
|
| |||||||||
| Terpene | Ginkgolide | C19H21NO4 | — | + | − | Short | — | In vitro/animal models | |
| Quinones | Tanshinone | C19H18O3 | Reduction in IK1 | − | − | — | — | In vitro/animal models | |
| Others | Crataegus | C20H27NO11 | Reduction in IKs and IKr | − | − | Prolong | — | In vitro/animal models | |
| Danshensu | C9H10O5 | − | − | — | Cx43 | In vitro/animal models | |||
| Omega-3 fatty acids | — | — | + | + | — | — | Humans-RCT | ||
| Allitridi | C6H10S2O | Reduction in IKr, Iks, hKv4.3, hKv1.5, and CNQ1/hKCNE1 | − | − | — | — | In vitro/animal models | ||
|
| |||||||||
| WXKL | Reduction in Ito | + | + | Prolong | — | Humans-RCT | |||
| SSYX | − | − | In vitro/animal models | ||||||
Pal-LPC = lysophosphatidylcholine; RCT = randomized controlled trial; Cx43 = gap junctional connexin 43; APD = action potential duration; WXKL = Wenxin-Keli; SSYX = Shensongyangxin.
Figure 1Schematic overview of the proposed antiarrhythmic mechanism of each natural drug agent. SR = sarcoplasmic reticulum. SERCA = SR Ca2+ATPase.